Actively Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Led by AstraZeneca · Updated on 2026-05-11
200
Participants Needed
21
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
CONDITIONS
Official Title
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent
- Age 18 years or older
- Histologically or cytologically confirmed limited stage small-cell lung cancer (Stage I-III, T any, N any, M0) suitable for definitive radiation
- ECOG performance status of 0 to 2 before the first durvalumab dose after CRT
- No disease progression after concurrent or sequential chemoradiation therapy
- Received platinum-based concurrent or sequential chemoradiation therapy followed by durvalumab consolidation as first-line treatment
- Durvalumab consolidation started within 3 months before enrollment, regardless of ongoing or discontinued treatment
You will not qualify if you...
- Treated with chemoradiation therapy only without durvalumab consolidation
- Received durvalumab or other anti-PD-1/PD-L1 antibodies during chemoradiation therapy
- Previously involved or currently/planning participation in other interventional anti-cancer clinical studies for LS-SCLC
- Prior treatment with immune therapies targeting PD-1, PD-L1, or PD-L2, except therapeutic anticancer vaccines
- Investigator judgment that patient is unlikely to comply with study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Research Site
Beijing, China
Actively Recruiting
2
Research Site
Cangzhou, China
Actively Recruiting
3
Research Site
Dongguan, China
Actively Recruiting
4
Research Site
Fuzhou, China
Actively Recruiting
5
Research Site
Guangzhou, China
Actively Recruiting
6
Research Site
Huzhou, China
Actively Recruiting
7
Research Site
Jinan, China, 250117
Actively Recruiting
8
Research Site
Jinan, China
Actively Recruiting
9
Research Site
Nanjing, China
Actively Recruiting
10
Research Site
Nanning, China
Actively Recruiting
11
Research Site
Ningbo, China
Actively Recruiting
12
Research Site
Shanghai, China
Actively Recruiting
13
Research Site
Shenyang, China
Actively Recruiting
14
Research Site
Shijiazhuang, China
Actively Recruiting
15
Research Site
Taiyuan, China
Actively Recruiting
16
Research Site
Tianjing, China
Actively Recruiting
17
Research Site
Tianjing, China
Terminated
18
Research Site
Wuhan, China
Actively Recruiting
19
Research Site
Wuxi, China
Actively Recruiting
20
Research Site
Yangzhou, China
Actively Recruiting
21
Research Site
Zhengzhou, China
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here